Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Chuvash polycythemia is a rare congenital form of polycythemia caused by homozygous R200W and H191D mutations in the VHL (von Hippel-Lindau) gene, whose gene product is the principal negative regulator of hypoxia-inducible factor. However, the molecular mechanisms underlying some of the hallmark abnormalities of Chuvash polycythemia, such as hypersensitivity to ... erythropoietin, are unclear. Here we show that VHL directly binds suppressor of cytokine signaling 1 (SOCS1) to form a heterodimeric E3 ligase that targets phosphorylated JAK2 (pJAK2) for ubiquitin-mediated destruction. In contrast, Chuvash polycythemia-associated VHL mutants have altered affinity for SOCS1 and do not engage with and degrade pJAK2. Systemic administration of a highly selective JAK2 inhibitor, TG101209, reversed the disease phenotype in Vhl(R200W/R200W) knock-in mice, an experimental model that recapitulates human Chuvash polycythemia. These results show that VHL is a SOCS1-cooperative negative regulator of JAK2 and provide biochemical and preclinical support for JAK2-targeted therapy in individuals with Chuvash polycythemia.
Mesh Terms:
Animals, Disease Models, Animal, Humans, Janus Kinase 2, Mice, Mutation, Polycythemia, Protein Multimerization, Pyrimidines, Sulfonamides, Suppressor of Cytokine Signaling Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
Animals, Disease Models, Animal, Humans, Janus Kinase 2, Mice, Mutation, Polycythemia, Protein Multimerization, Pyrimidines, Sulfonamides, Suppressor of Cytokine Signaling Proteins, Ubiquitin-Protein Ligases, Von Hippel-Lindau Tumor Suppressor Protein
Nat. Med.
Date: Jul. 01, 2011
PubMed ID: 21685897
View in: Pubmed Google Scholar
Download Curated Data For This Publication
140487
Switch View:
- Interactions 8
- PTM Genes 1